TG Therapeutics, Inc.’s cover photo
TG Therapeutics, Inc.

TG Therapeutics, Inc.

Biotechnology Research

Morrisville, North Carolina 41,924 followers

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.

About us

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

Website
http://www.tgtherapeutics.com/
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Morrisville, North Carolina
Type
Public Company
Founded
2011
Specialties
Biotechnology, multiple sclerosis, b-cell diseases, ublituximab, subcutaneous, RMS, and Azer-Cel

Locations

Employees at TG Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding